BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth
1. BNTX reported a Q2 loss of $1.82 per share, improving from last year. 2. Sales reached $295.69M, beating consensus estimates of $147.90M. 3. R&D expenses decreased due to a focus on key programs. 4. The company reaffirms its 2025 revenue guidance of 1.7B-2.2B euros. 5. BNTX has strategic collaborations with BMS and a pending acquisition of CureVac.